These prices can be a significant burden for patients who need long-term treatment, especially since both drugs are administered weekly
A handful of studies and simulations, though, suggest that any future health savings will still be dwarfed by the cost of the drugs, at least at current prices
In an announcement of the study on the Vanderbilt website, lead author Khrysta Baig described this as a purely hypothetical scenario, but one that underscores that at current prices, these medications cannot be the only way or even the main way we address obesity as a society. In a more conservative estimate, Bhaig and coauthors consider a case where only about 10% of those eligible for obesity treatment opted for semaglutide, which would result in $27 billion in new costs
Its especially important to reach out if: The urine odor is severe and persists for more than a few months
The Data is a part of the AHFS Drug Information
Nature 458, 762765